Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Yaxian Yao"'
Autor:
Yuanyuan Xu, Xiaoke Chen, Jianghao Ren, Mingyang Zhu, Ruonan Li, Jiazheng Huang, Yaxian Yao, Zhengmin Zhang, Qiang Tan
Publikováno v:
Cancer Medicine, Vol 12, Iss 12, Pp 13054-13062 (2023)
Abstract Objectives The risk and beneficial factors of early discharge after thoracoscopic anatomic lung cancer surgery are unknown, and this study aims to investigate predictors and associated 30‐day readmission for early discharge. Methods We per
Externí odkaz:
https://doaj.org/article/34253b225a624717a4d1a1f9362f2693
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
ObjectivesRecent clinical studies have demonstrated that immunotherapy-based neoadjuvant therapy have promising effectiveness for patients with resectable non-small cell lung cancer (NSCLC) in terms of pathologic response. Therefore, we performed thi
Externí odkaz:
https://doaj.org/article/d20732ea318f46b9958ff3dc9c30f761
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundThis open, observational clinical study aimed to investigate the efficacy, safety and survival outcomes of neoadjuvant chemotherapy, neoadjuvant immunotherapy with(out) chemotherapy and neoadjuvant targeted therapy among resectable stage II
Externí odkaz:
https://doaj.org/article/b286b098d079430691210c13a5b2d76d
Autor:
Linping Gu, Xue Wang, Yile Sun, Yunhua Xu, Xiaomin Niu, Ruiying Zhao, Yaxian Yao, Hong Jian, Yuchen Han, Jinwang Wei, Zhiwei Chen, Shun Lu
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
BackgroundAn open, observational, three-arm clinical study aimed at investigating the efficacy of different neoadjuvant therapies (neoadjuvant immunotherapy with(out) chemotherapy, neoadjuvant chemotherapy, and neoadjuvant targeted therapy) in operab
Externí odkaz:
https://doaj.org/article/5c8b68fd6dea444a961b899d3c1543bf
Autor:
Asma Khanniche, Yi Yang, Jie Zhang, Shiqing Liu, Liliang Xia, Huangqi Duan, Yaxian Yao, Bingrong Zhao, Guo‐Ping Zhao, Chengping Hu, Ying Wang, Shun Lu
Publikováno v:
Clinical & Translational Immunology, Vol 11, Iss 7, Pp n/a-n/a (2022)
Abstract Objectives Despite remarkable advances in the treatment of non‐small cell lung cancer (NSCLC) with anti‐programmed death (PD)‐1 therapy; only a fraction of patients derives durable clinical benefit. In this study, we investigated wheth
Externí odkaz:
https://doaj.org/article/629ef8d4f71a4a4a8c3f42f16507f036
Autor:
Hui Dong, Qiang Tan, Yuanyuan Xu, Yongqiang Zhu, Yaxian Yao, Yuezhu Wang, Chong Li, Hong Li, Guoqing Zhang, Yan Xiong, Meihua Ruan, Jiadong Zhao, Weirong Jin, Lungen Lu, Shun Lu
Publikováno v:
iScience, Vol 25, Iss 1, Pp 103638- (2022)
Summary: Microbiota-host interaction plays an important role in cancer predisposing, initiation, progression, and response to therapy. Here, we explored the composition of lung tissue microbiota in 143 Chinese patients through conducting 16S rRNA gen
Externí odkaz:
https://doaj.org/article/e0488aa159c8471aa9f8a13c55da9e76
Autor:
Liliang Xia, Limin Guo, Jin Kang, Yi Yang, Yaxian Yao, Weimin Xia, Ruiming Sun, Shun Zhang, Wenfeng Li, Yuer Gao, Hongyan Chen, Ziming Li, Jinji Yang, Shun Lu, Ying Wang
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
Tumor-infiltrating B cells and tertiary lymphoid structures have been identified to predict the responses to immune checkpoint inhibitors (ICIs) in cancer immunotherapy. Considering the feasibility of sample collection, whether peripheral B cell sign
Externí odkaz:
https://doaj.org/article/fb538cfc95174cd095318619e326d25a
Autor:
Xiaoqun Nie, Liliang Xia, Fang Gao, Lixia Liu, Yi Yang, Yingying Chen, Huangqi Duan, Yaxian Yao, Zhiwei Chen, Shun Lu, Ying Wang, Chen Yang
Publikováno v:
Frontiers in Molecular Biosciences, Vol 8 (2021)
Background: Despite remarkable success of immunotherapies with checkpoint blockade antibodies targeting programmed cell death protein 1 (PD-1), the majority of patients with non-small-cell lung cancer (NSCLC) have yet to receive durable benefits. We
Externí odkaz:
https://doaj.org/article/307b214561e1409d8efdb7a4edbc27ad
Publikováno v:
Translational Cancer Research
Background The aim was to explore the interaction among chemokine (C-X-C motif) ligand (CXCL) 1/2/8 expressions, and their associations with clinicopathologic features and survival profiles in non-small cell lung cancer (NSCLC) patients. Methods The
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::799c7482abe8cce0026c7cb0b861572e
https://doi.org/10.21037/tcr-20-2539
https://doi.org/10.21037/tcr-20-2539
Autor:
Huangqi Duan, Hui Wang, Zhiwei Chen, Weimin Xia, Hong Li, Ying Wang, Chengcheng Yao, Shun Lu, Liliang Xia, Ruiming Sun, Yi Yang, Qiong Zhao, Sheng He, Yaxian Yao, Mingjiao Sun
Publikováno v:
Science China Life Sciences. 64:1590-1601
Limited benefit population of immune checkpoint inhibitors makes it urgent to screen predictive biomarkers for stratifying the patients. Herein, we have investigated peripheral CD4+ T cell signatures in advanced non-small cell lung cancer (NSCLC) pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8d293b0a3d4c9bcd8de76cf6d973c7fa
https://doi.org/10.1007/s11427-020-1861-5
https://doi.org/10.1007/s11427-020-1861-5